TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
← New search

SNSE

Sensei Biotherapeutics Inc

NASDAQCommon Stock
$22.87
-7.30%today

No SEC filings for this security

Sensei Biotherapeutics Inc is a foreign or OTC-listed security (NASDAQ) that doesn't file with the SEC, so the grounded research view — financials, filings, insider activity and the call — isn't available. Price and news only.

Key stats

52-week range$6.80 – $35.07
6.8052-week35.07
Market cap
$18.6M
Volume
146K
1Y return
+166.55%
Beta
-0.23

Price · 1Y

$22.87▲ +166.55%
over 1Y
L $6.80H $35.07

Recent news

market news →
Top Biotech Gainers: SNSE Awaits Data In 2H, STTK To Begin Crohn's Trial In Q3, ALMS On WatchBullish
nasdaq.com· 2026-06-15
Top Biotech Gainers: REPL On Track, SNSE Awaits Phase 2 Data, Keep An Eye On CCCC, IMRX SoarsBullish
nasdaq.com· 2026-06-01
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming TherapiesBullish
globenewswire.com· 2026-05-14
Sensei Biotherapeutics (SNSE): Best Performing NASDAQ Stocks According to Wall Street AnalystsBullish
finance.yahoo.com· 2026-05-05
Most and least shorted small-to-mid-cap stocksBullish
seekingalpha.com· 2026-04-06
Sensei Biotherapeutics GAAP EPS of -$16.72Bullish
seekingalpha.com· 2026-03-30
The Patent Cliff is Coming, Driving Smart Money Towards Precision OncologyBearish
globenewswire.com· 2026-03-19
Catalyst Watch: Nvidia blockbuster, JPMorgan event, and reactions to the tariff resetBullish
seekingalpha.com· 2026-02-20

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.